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Klebsiella pneumoniae strains of phylogenetic groups Kp1 to Kp7 have been classified as K. pneumoniae *sensu stricto*, K. quasipneumoniae subsp. *quasipneumoniae*, K. variicola subsp. *variicola*, K. quasipneumoniae subsp. *similipneumoniae*, K. variicola subsp. *tropicalensis*, K. quasivariicola, and K. africanensis, respectively ([@B1]). Specifically, K. quasipneumoniae has been recognized as an opportunistic pathogen that can acquire clinically relevant antibiotic resistance genes ([@B2][@B3][@B5]). Here, we report draft genome sequences of two Klebsiella quasipneumoniae strains producing KPC-2 and NDM-1 carbapenemases, which confer resistance to all clinically relevant β-lactam antibiotics.

Carbapenem-resistant K. quasipneumoniae strains 34H and Kp1345 were isolated in 2014 from perfusion fluid ([@B6]) and in 2017 from a rectal swab for surveillance culture ([@B7]), respectively, from patients hospitalized in a teaching hospital in Brazil. Species identification was performed by matrix-assisted laser desorption ionization--time of flight mass spectrometry ([@B8]), and antimicrobial susceptibility was determined with the Vitek 2 system (bioMérieux, France) according to the manufacturer's instructions. Carbapenemase production was detected by the Blue-Carba test ([@B9]) ([Fig. 1](#fig1){ref-type="fig"}) and modified Hodge test ([@B10]), whereas carbapenemase activity of NDM-1 and KPC-2 β-lactamases was confirmed by EDTA and dipicolinic acid inhibition assays, respectively ([@B11][@B12][@B13]). Additionally, *bla*~NDM-1~ and *bla*~KPC-2~ genes were identified by PCR amplification and direct DNA sequencing of PCR products ([@B14]).

![Representative results of the Blue-Carba test for carbapenemase-producing (B, C, and D) and non-carbapenemase-producing (A) bacteria, with test solutions (left) and negative-control solutions (right). (A) K. pneumoniae ATCC BAA1706 (carbapenemase-negative control); (B) K. pneumoniae ATCC BAA1705 (carbapenemase \[KPC\]-positive control); (C) K. quasipneumoniae subsp. *quasipneumoniae* 34H (this study) (carbapenemase \[KPC-2\] positive); (D) K. quasipneumoniae subsp. *similipneumoniae* Kp1345 (this study) (carbapenemase \[NDM-1\] positive). The images were obtained after 2 h of incubation. Carbapenemase production was assessed by the Blue-Carba test method ([@B9]), which relies on the detection, in a bacterial extract, of hydrolysis of the carbapenem β-lactam ring through the acidification of a bromothymol blue test solution, used as a color indicator. The test solution consists of an aqueous solution of 0.04% bromothymol blue adjusted to pH 6.0, 0.1 mM ZnSO~4~, and 3 mg/ml imipenem, with a final pH of 7.0. A negative-control solution (0.04% bromothymol blue solution \[pH 7.0\]) is used to control for the influence of bacterial components or products on the pH of the solution. A loop (approximately 5 μl) of a pure bacterial culture recovered from Mueller-Hinton agar was directly suspended in 100 μl of both test and negative-control solutions in a 96-well microtiter plate and incubated for 2 h at 37°C with agitation (150 rpm). Carbapenemase activity was revealed when the test solution and negative-control wells were yellow and blue, respectively. The non-carbapenemase-producing strain (negative control) remained blue or green with both solutions.](MRA.00089-20-f0001){#fig1}

For whole-genome sequencing (WGS) analyses, the strains were streaked to single colonies on MacConkey agar plates and then grown for 18 h at 37°C in 3 ml of lysogeny broth. Total genomic DNA was extracted using a PureLink quick gel extraction kit (Life Technologies, CA) and used for library preparation with a Nextera XT kit (Illumina, San Diego, CA). In addition, the DNA was quantified with a double-stranded DNA high-sensitivity assay using a Qubit 2.0 fluorometer (Life Technologies) according to the manufacturer's instructions. Subsequently, sequencing was performed on an Illumina NextSeq PE instrument using a paired-end (150-bp) library. The short reads were handled using FastQC v.0.11.3 (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc>) and Trimmomatic v.0.32 ([@B15]). *De novo* assembly was performed using SPAdes v.3.9 ([@B16]), and draft genome annotations were made using NCBI PGAP v.3.2 (<https://www.ncbi.nlm.nih.gov/genome/annotation_prok>). Contamination levels were checked using CheckM v.1.0.3 with default settings ([@B17]). WGS data were analyzed using PlasmidFinder v.2.0 ([@B18]), ResFinder v.3.2 ([@B19]), and SpeciesFinder v.2.0 ([@B20]) tools (<http://www.genomicepidemiology.org>). Default parameters were used for all software.

Genome sequence analysis identified K. quasipneumoniae subsp. *quasipneumoniae* (strain 34H) and K. quasipneumoniae subsp. *similipneumoniae* (strain Kp1345), presenting a total of 16,501,776 and 10,695,728 paired-end reads assembled into 183 and 487 contigs, with 247.0× and 320.0× coverage, respectively. The *N*~50~ values obtained for strains 34H and Kp1345 were 84,397 and 122,604 bp, with GC contents of 57.6% and 56.8%, respectively. In brief, strain 34H presented a genome size calculated as 5,666,228 bp, with 5,134 protein-coding sequences, 82 tRNAs, 22 rRNAs, 12 noncoding RNAs, and 49 pseudogenes, whereas Kp1345 presented a genome size of 5,921,292 bp, with 5,134 protein-coding sequences, 82 tRNAs, 22 rRNAs, 12 noncoding RNAs, and 49 pseudogenes. CheckM results showed 99.99% and 99.938% completeness and 0.952% and 1.061% contamination for the 34H and KPC1345 genomes, respectively.

In summary, we present the draft genome sequences of two carbapenem-resistant Klebsiella quasipneumoniae strains displaying broad resistomes for β-lactams (i.e., *bla*~KPC-2~, *bla*~OKP-A-6~, *bla*~OKP-B-2~, *bla*~NDM-1~, and *bla*~CTX-M-15~) and other medically important antibiotics. These data could contribute to a better understanding of acquired resistance in K. quasipneumoniae.
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The genome sequences of K. quasipneumoniae subsp. *quasipneumoniae* strain 34H and K. quasipneumoniae subsp. *similipneumoniae* strain Kp1345 have been deposited in GenBank under accession numbers [NZ_VDFT00000000](https://www.ncbi.nlm.nih.gov/nuccore/NZ_VDFT00000000) (SRA number [SRR9950479](https://www.ncbi.nlm.nih.gov/sra/SRR9950479)) and [NZ_VDFZ00000000](https://www.ncbi.nlm.nih.gov/nuccore/NZ_VDFZ00000000) (SRA number [SRR9942580](https://www.ncbi.nlm.nih.gov/sra/SRR9942580)), respectively. For a spreadsheet containing details of antibiotic resistance genes, plasmid incompatibility groups, and CheckM and Qubit results, see Table S1 at <https://doi.org/10.6084/m9.figshare.11675805>.
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